Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 Infection
- 1 July 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (3) , 251-259
- https://doi.org/10.1097/00126334-200107010-00006
Abstract
To identify the effects of substance abuse status (active, former, and never) on utilization of highly active antiretroviral therapy (HAART), medication adherence, and virologic and immunologic responses to therapy. Prospective cohort study of 764 HIV-1-infected patients who attended an urban HIV clinic and participated in a standardized interview. Past utilization of HAART, self-reported nonadherence with antiretroviral therapy, and changes in HIV-1 RNA level and CD4+ lymphocyte count relative to prior peak and nadir, respectively. Forty-four percent of active drug users failed to utilize HAART compared with 22% of former drug users and 18% of non-drug users (p <.001 for both comparisons). Among participants who were taking antiretroviral therapy when interviewed, active drug users were more likely to report medication nonadherence (34% vs. 24% of nonusers and 17% of former users), had a smaller median reduction in HIV-1 RNA from baseline (0.8 log10 copies/ml vs. 1.7 in nonusers and 1.6 in former users), and had smaller median increases in CD4+ lymphocyte count from baseline (65 cells/mm3 vs. 116 in nonusers and 122 in former users) (p <.05 for all comparisons with active users). Active drug use was strongly associated with underutilization of HAART, nonadherence, and inferior virologic and immunologic responses to therapy, whereas former drug users and non-drug users were similar in all outcomes. Effective strategies are needed that integrate HIV-1 and substance abuse treatments.Keywords
This publication has 45 references indexed in Scilit:
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort StudyAIDS, 1999
- Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Natural history of HIV infection in the_era of combination antiretroviral therapyAIDS, 1999
- Variations in the Care of HIV-Infected Adults in the United StatesPublished by American Medical Association (AMA) ,1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Self-reported Antiretroviral Therapy in Injection Drug UsersJAMA, 1998
- Barriers to Use of Free Antiretroviral Therapy in Injection Drug UsersJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Medical Care for Injection-Drug Users with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1994